Genome Editing in Human Cells: The Dos and and Don'ts
Illustration: Sisters of Design
New techniques in molecular biology that enable targeted interventions in the genome are opening up promising new possibilities for research and application. The ethical and legal ramifications of these methods, known as “genome editing” and ”genome surgery”, need to be discussed throughout society, particularly with regard to research on human cells. To foster discussion on these issues in Germany, a group of experts from the German National Academy of Sciences Leopoldina has written a Discussion Paper entitled “Ethical and legal assessment of genome editing in research on human cells”, published recently.
The German Embryo Protection Act prohibits research on human embryos in Germany. However, the act, last amended in 2011, does not cover all issues raised by these new methods in genome surgery. The authors have published the Discussion Paper to highlight the urgent need for broad public debate on genome editing in medical research. The paper is intended to stimulate this debate, which is already being extensively conducted on an international level. In the opinion of the authors, the use of genome editing in research on human embryonic development is useful because there are significant differences in the embryogenesis of humans and animals. The authors also advocate relevant basic research to enable evidence-based assessment of the benefits and risks associated with germline therapies and germline effects.
The scientists nonetheless narrowly limit the scope of implementation of such research projects. They propose that only embryos from reproduction medicine that are no longer going to be used and therefore do not have a realistic chance of life should be made available for research. The paper rejects efforts to use genome editing for enhancement as this involves incalculable risks and raises fundamental ethical and social questions.
The discussion paper can be accessed here - http://www.leopoldina.org/fileadmin/redaktion/Publikationen/Diskussionen/2017_Diskussionspapier_GenomeEditing.pdf
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.